![Cells | Free Full-Text | Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment Cells | Free Full-Text | Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment](https://pub.mdpi-res.com/cells/cells-10-00323/article_deploy/html/images/cells-10-00323-g001.png?1612516155)
Cells | Free Full-Text | Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment
![Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience | SpringerLink Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12325-017-0612-x/MediaObjects/12325_2017_612_Fig1_HTML.gif)
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience | SpringerLink
![Rituximab, an Anti‐CD20 Monoclonal Antibody: History and Mechanism of Action - Pescovitz - 2006 - American Journal of Transplantation - Wiley Online Library Rituximab, an Anti‐CD20 Monoclonal Antibody: History and Mechanism of Action - Pescovitz - 2006 - American Journal of Transplantation - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/57302335-10b7-4e3f-b402-4d25811a8f1f/ajt_1288_f3.gif)
Rituximab, an Anti‐CD20 Monoclonal Antibody: History and Mechanism of Action - Pescovitz - 2006 - American Journal of Transplantation - Wiley Online Library
![Immunosuppressive therapy with rituximab in common variable immunodeficiency | Clinical and Molecular Allergy | Full Text Immunosuppressive therapy with rituximab in common variable immunodeficiency | Clinical and Molecular Allergy | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12948-019-0113-3/MediaObjects/12948_2019_113_Fig1_HTML.png)
Immunosuppressive therapy with rituximab in common variable immunodeficiency | Clinical and Molecular Allergy | Full Text
![Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial - The Lancet Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial - The Lancet](https://www.thelancet.com/cms/asset/bf64c07e-1d5b-43c3-98df-5b977e6d8a6a/gr1.jpg)
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial - The Lancet
![Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis | Nature Reviews Rheumatology Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis | Nature Reviews Rheumatology](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fncprheum0424/MediaObjects/41584_2007_Article_BFncprheum0424_Fig2_HTML.jpg)
Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis | Nature Reviews Rheumatology
![B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience | Annals of the Rheumatic Diseases B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience | Annals of the Rheumatic Diseases](https://ard.bmj.com/content/annrheumdis/62/suppl_2/ii55/F1.large.jpg)